Imcyse raises €21M and opens its capital to its new American partner, Pfizer. Very good news for the Liège-based biotech company Imcyse. Indeed, the biotech has developed an active immunotherapy technology that allows to tackle autoimmune diseases such as multiple sclerosis, type 1 diabetes or rheumatoid arthritis. A licensing agreement has just been signed with[…]
This is a world first in the field of orthopaedic surgery: surgeons at Cliniques universitaires de Saint-Luc repaired the tibia bone of a 5-year-old child using a bone graft implant, a technology developed by the UCLouvain spin-off Novadip Biosciences. The child had congenital nonunion of the tibia, a rare and disabling disease. He was[…]
Great news for Novadip published in L’Echo and Trends Tendances. Novadip Biosciences – biotech active in cell therapy – has recorded very encouraging results for its product candidate intended to repair large non-healing fractures of the lower limbs in adults. The UCLouvain spin-off has developed a revolutionary process for reconstructing bones from stem cells drawn from the patient’s fat.[…]
Liège, Belgium and Grenoble, France, March 3, 2020 – PDC*line Pharma, a clinical stage biotech company developing a new class of potent and scalable active immunotherapies for cancers, announces today that the first patient was dosed with its innovative medicinal product candidate PDC*lung01 in a phase I/II trial in non-small cell lung cancer (NSCLC). This patient is under[…]
Our customer Imcyse is announcing to the world their excellent first-in-human clinical results in Type 1 Diabetes. Imcyse reports successful first-in-human Phase 1b study in type 1 diabetes with IMCY-0098